Physician profile
Kai Li
NPI 1427153238
$1,900.76
in general payments reported to CMS, 2019-2025
22 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $402 · 2021: $194 · 2022: $223 · 2023: $442 · 2024: $23.76 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.68 |
| Education | $118.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $315.03 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $192.69 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $182.33 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $156.19 | 2019-2023 | |
| Lilly USA, LLC | $133.92 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $123.81 | 2020-2023 | Rexulti |
| Glaxosmithkline, LLC. | $120.66 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $69.85 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $58.85 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.22 | 2019 | |
| Abbott Laboratories | $37.03 | 2022 | |
| Horizon Therapeutics Plc | $30.42 | 2019-2020 | |
| Amgen INC. | $28.13 | 2025 | Otezla, Repatha |
| Lundbeck LLC | $28.08 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $27.35 | 2019-2020 | |
| Philips North America LLC | $26.53 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $21.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.82 | 2023 | Spravato |
| Scilex Pharmaceuticals INC. | $20.13 | 2019 | |
| Boston Scientific Corporation | $16.63 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.